545 CONCORD AVENUE, CAMBRIDGE, MA
Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
MetaVia Inc. Files Prospectus Supplement for $4 Million Common Stock Offering
Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
MetaVia Inc. Stockholders Approve First Amendment to Equity Incentive Plan
Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
To Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
Reports First Quarter 2026 Financial Results and Provides Corporate Update
To Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
S-1MEF
Free Writing Prospectus
Submission Upload
Correspondence